Skip to Main Content Skip to Site Map Skip to Accessibility Statement


Trial Acronym EMERALD
Clinical Area Diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR)
Description Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy
Status Closed

The EMERALD Trial is now complete.  If you wish to discuss the EMERALD study, please email

  • Recruitment
    Date Opened to Recruitment Expected 1st October 2017
    Target Recruitment 416
    Recruitment to date 274
    Date Closed to Recruitment N/A
    No. of Sites 13
  • Trial Design
    Trial Design Prospective, cross-sectional diagnostic study
    Study Aim EMERALD aims to determine the diagnostic performance and cost-effectiveness of a new form of surveillance for people with stable DMO and/or PDR, using the current standard of care as the reference standard.
    The specific objectives of this study are to evaluate the new surveillance pathway to:1. Quantify and compare the diagnostic accuracy (in terms of sensitivity, specificity, overall agreement, positive and negative likelihood ratios) of the new pathway of surveillance (ophthalmic grader pathway) using the current standard of care pathway as the reference standard. This will be done separately for DMO and PDR.
    2. Assess acceptability of the new surveillance pathway.
    3. Determine the proportion of patients requiring subsequent full clinical assessment by an ophthalmologist under the new pathway.
    4. Determine the proportion of patients unable to undergo imaging tests, with images of inadequate quality and indeterminate findings under the new pathway.
    5. Establish relative cost-effectiveness of the new surveillance pathway.
  • Chief Investigator
    Chief Investigator Professor Noemi Lois
  • Sponsor & Funder
    Sponsors Belfast Health and Social Care Trust
    Funder National Institute of Health Research (NIHR)

Quick Links